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Vascular permeability is a complex process involving the
coordinated regulation of multiple signaling pathways in the
endothelial cell. It has long been documented that vascular
endothelial growth factor (VEGF) greatly enhancesmicrovascu-
lar permeability; however, the molecular mechanisms control-
ling VEGF-induced permeability remain unknown. Treatment
of microvascular endothelial cells with VEGF led to an increase
in reactive oxygen species (ROS) production. ROS are required
for VEGF-induced permeability as treatment with the free rad-
ical scavenger,N-acetylcysteine, inhibited this effect. Addition-
ally, treatment with VEGF caused ROS-dependent tyrosine
phosphorylation of both vascular-endothelial (VE)-cadherin
and -catenin. Rac1 was required for the VEGF-induced
increase in permeability and adherens junction protein phos-
phorylation. Knockdown of Rac1 inhibited VEGF-induced ROS
production consistent with Rac lying upstream of ROS in this
pathway. Collectively, these data suggest that VEGF leads to a
Rac-mediated generation of ROS, which, in turn, elevates the
tyrosine phosphorylation of VE-cadherin and -catenin, ulti-
mately regulating adherens junction integrity.
Endothelial cells line the inside of blood vessels and serve as a
barrier between circulating blood and the surrounding tissues.
Endothelial permeability is mediated by two pathways: the
transcellular pathway and the paracellular pathway. In the tran-
scellular pathway material passes through the cells, whereas in
the paracellular pathway fluid and macromolecules pass
between the cells. The paracellular pathway is regulated by the
properties of endothelial cell-cell junctions (1–3). Changes in
the permeability of this barrier are tightly regulated under nor-
mal physiological conditions. However, dysregulated vascular
permeability is observed in many life-threatening conditions,
including heart disease, cancer, stroke, and diabetes.
VEGF2 was first discovered as a potent vascular permeability
factor that stimulated a rapid and reversible increase in micro-
vascular permeability without damaging the endothelial cell (4,
5). VEGF was later shown to be a selective growth factor for
endothelial cells, capable of promoting migration, growth, and
survival (6). Considerable progress has been made toward
understanding the signaling events by which VEGF promotes
growth and survival (7). However, the mechanism through
which VEGF promotes microvascular permeability remains
incompletely understood.
VE-cadherin is an endothelial cell-specific adhesion mole-
cule that connects adjacent endothelial cells (8, 9). While the
barrier function of the endothelium is supported by multiple
cell-cell adhesion systems, disruption of VE-cadherin is suffi-
cient to disrupt intercellular junctions (9–11). Earlier studies
have demonstrated increased permeability both in vitro and in
vivo after treatment with VE-cadherin-blocking antibodies (9,
12). Additionally, VE-cadherin is required to prevent disassem-
bly of blood vessel walls (11, 13) and to coordinate the passage
of macromolecules through the endothelium (14, 15). Tyrosine
phosphorylation may provide the regulatory link, as increased
phosphorylation of cadherins and potential dissociation of the
cadherin/catenin complex results in decreased cell-cell adhe-
sion and increased permeability (16, 17).
Recent evidence has demonstrated that Rac1-induced reac-
tive oxygen species (ROS) disrupt VE-cadherin based cell-cell
adhesion (18). The mechanisms by which ROS affect endothe-
lial permeability have not been fully characterized. VEGF has
been reported to induce NADPH oxidase activity and induce
the formation of ROS (19, 20). A direct link between Rac and
ROS in a non-phagocytic cell was shown in 1996, when it was
demonstrated that activatedRac1 resulted in the increased gen-
eration of ROS in fibroblasts (21). Several studies have subse-
quently implicated Rac-mediated production of ROS in a vari-
ety of cellular responses, in particular in endothelial cells (22,
23). These data suggest that ROS may play a critical role in
integrating signals from VEGF and Rac to regulate the phos-
phorylation of VE-cadherin and ultimately the integrity of the
endothelial barrier.
In the present study we sought to determine the mecha-
nism by which VEGF regulates microvascular permeability.
Our results show that VEGF treatment of human microvas-
cular endothelial cells results in the Rac-dependent produc-
* This work was supported, in whole or in part, by National Institutes of Health
Grants HL080166 and HL045100 (to K. B.).
1 Supported by a postdoctoral training grant and by NIH Training Grant
T32-CA-09156-34. To whom correspondence should be addressed: Uni-
versity of North Carolina, 12-026 Lineberger Cancer Center, Chapel Hill,
NC 27599-7295. Tel.: 919-966-5783; Fax: 919-966-3015; E-mail:
ebenson@med.unc.edu.
2 The abbreviations used are: VEGF, vascular endothelial growth factor; ROS,
reactive oxygen species; PTP, protein-tyrosine phosphatase; VE-cadherin,
vascular-endothelial cadherin; GFP, green fluorescent protein; DCF, 6-car-
boxy-2,7-dichlorofluorescein diacetate di(acetoxymethyl ester); HMVEC,
human pulmonary microvessel endothelial cell; WT, wild type; siRNA, small
interference RNA; FITC, fluorescence isothiocyanate; NAC, N-acetylcys-
teine; DPI, diphenyleneiodonium chloride; PAK, p21-activating kinase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 38, pp. 25602–25611, September 18, 2009
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
25602 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284 • NUMBER 38 • SEPTEMBER 18, 2009
tion of ROS and the subsequent tyrosine phosphorylation of
VE-cadherin and -catenin. The phosphorylation of VE-
cadherin and -catenin are dependent on Rac and ROS and
result in decreased junctional integrity and enhanced vascu-
lar permeability.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—Unless otherwise stated all
chemicals were obtained from Sigma. DCF was obtained
from Molecular Probes (Eugene, OR). Recombinant human
VEGF165 was purchased from R&D Systems (Minneapolis,
MN). DPI was purchased from Calbiochem. The total VE-
cadherin antibody and the p120 catenin antibody were
obtained from Santa Cruz Biotechnology, and the phospho-
specific VE-cadherin antibodies were from BIOSOURCE
(Camarillo, CA). The antibody against Rac1 was from BD Bio-
sciences. The -catenin PY654 antibody was from AbCam.
Monoclonal antibody to phosphotyrosine (clone 4G10) was
obtained from Upstate Biotechnology.
Cell Culture—Human pulmonary microvessel endothelial
cells (HMVECs) were obtained from Lonza and grown in Lon-
za’s EGM-2-MVmedium on collagen-coated (20 g/ml) tissue
culture dishes according to the manufacturer’s instructions.
ROS Generation—Formation of ROS was monitored by the
conversion of non-fluorescent 6-carboxy-2,7-dichlorodihy-
drofluorescein diacetate di(acetoxymethyl ester) to fluorescent
DCF. Cells were loaded with 5 M DCF in serum-free medium
for 30 min at 37 °C. After loading, cells were washed twice with
phosphate-buffered saline, and incubated for an additional 20
min at 37 °C to allow for dye de-esterification. Cells were stim-
ulated as described in the figure legends. Fluorescence was
determined using a fluorometer with an excitation of 485 and
an emission of 520.
siRNA Transfection—Cells plated at 50% confluence and
left overnight were transfected with siRNA (Dharmacon) at a
concentration of 25 nM using Oligofectamine (Invitrogen)
according to the manufacturer’s instructions. A non-targeting
siRNA (Dharmacon) was used as a control. Cells were trans-
fected for 4 h in serum-free medium, following which 1.5 ml of
EGM-2MV was added. Cells were harvested after 72 h.
Adenoviral Infection of HMVECs—Wild-type VE-cadherin,
VE-cadherin Y658F, VE-cadherin Y731F, and VE-cadherin
Y658F/Y731F were generated as previously described (24).
HMVECswere infectedwith adenovirus for 48 h in EGM-2MV.
Infection efficiency (85%) was monitored through the visual-
ization of GFP, which is coexpressed by these recombinants.
FITC-Dextran Flux—HMVECs were grown to confluence
for aminimum of 3 days in the top well of a Transwell filter (0.4
M, 12-mm diameter, Corning). Cells were serum-starved for
2 h before treatment with VEGF. Treatment doses and times
are as detailed in the figure legends. 10-kDa FITC-dextran
(Molecular Probes) was added to the top chamber of the Tran-
swell for a final concentration of 1 mg/ml. After 1 h, as sample
was removed form the bottom compartment and read in a flu-
orometer (FluorStarOptima, BMGLabtech, excitation 485 nm,
emission 520 nm).
Immunofluorescence and Microscopy—HMVECs were
grown on collagen-coated coverslips. Cells were then treated
with NAC for 2 h before treatment with 10 ng/ml VEGF for 15
min. After VEGF treatment cells were fixed for 15 min in 3%
paraformaldehyde, permeabilized in 0.3% Triton X-100, and
blocked for 30 min in 2% bovine serum albumin. To visualize
VE-cadherin cells were stained with a monoclonal antibody
against VE-cadherin (Santa Cruz Biotechnology) followed by
goat anti-mouse Alexa 488 (Molecular Probes). Immunofluo-
rescence images were taken with a Zeiss axiovert 200Mmicro-
scope equipped with a Hamamatsu ORCA-ERAG digital cam-
era and Metamorph workstation (Universal Imaging Corp.).
Rac1 Activity Assays—Cells were stimulated as indicated in
the figure legends. After stimulation cells were kept on ice,
washed with ice-cold phosphate-buffered saline, and assayed
for Rac activation with glutathione S-transferase-p21-activat-
ing kinase, as described by Sander et al. (62). The beads were
washed four times with lysis buffer, and after the final wash
beads were resuspended in sample buffer. Samples were then
analyzed by SDS-PAGE.
Immunoprecipitation and Immunoblotting—Cell layers were
serum-starved for 2 h before stimulation with VEGF. Treat-
ment doses and times are provided in the figure legends. For
immunoprecipitation, cells were extracted on ice for 30 min in
lysis buffer (10mMTris, pH7.4, 150mMNaCl, 1%TritonX-100,
0.5% Nonidet P-40, protease, and phosphatase inhibitors).
After preclearing with protein A/G-agarose beads, lysates were
incubated with antibodies to VE-cadherin, p120 catenin, or
-catenin for 2 h at 4 °C. After washing three times, the beads
were resuspended in sample buffer, boiled for 10 min, and ana-
lyzed by Western blotting. For whole cell lysate analysis, cells
were rinsed in phosphate-buffered saline and lysed in sample
buffer. Lysates were electrophoresed into SDS-PAGE gels. Pro-
teins were transferred to nitrocellulosemembranes (Schleicher
and Schuell Bioscience) and processed for Western analysis
using the antibodies described in the figure legends. Bound
antibodies were detected by enhanced chemiluminescence. For
quantification of Western blots, intensity values of bands were
measured from three different repeats for each experiment
using ImageJ (National Institutes of Health).
RESULTS
To determine if VEGF treatment caused an increase in the
production of ROS inHMVECswe directlymonitored intracel-
lular ROS formation, using the conversion of the non-fluores-
cent 6-carboxy-2,7-dichlorodihydrofluoroscein to DCF. As
seen in Fig. 1A, treatment of HMVECs with increasing doses of
VEGF stimulated a dose-dependent increase in ROS produc-
tion as demonstrated by a net increase in cell fluorescence.
H2O2, a known ROS, was used as a positive control. The time
course of VEGF-induced ROS generation was then examined.
ROS generation was observed as early as 5 min after treatment
with VEGF (Fig. 1B). To confirm that the increase in DCF flu-
orescence observed upon VEGF treatment was due to an
increase in ROS generation the free radical scavenger, NAC,
was used. HMVECs were treated with increasing doses of NAC
before treatment with VEGF. ROS generation was then meas-
ured by DCF fluorescence (Fig. 1C). As expected, treatment
with NAC caused a dose-dependent decrease in DCF fluores-
cence confirming that the increase fluorescence was due to an
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increase in ROS generation. Inmany cell types, including endo-
thelial cells themajor producer of ROS is NADPH oxidase (25).
To determine if NADPH oxidase may be involved in VEGF-
induced ROS production the flavoprotein inhibitor, DPI, was
used to inhibit NADPH oxidase activity. Treatment with DPI
caused a dose-dependent decrease in ROS production, suggest-
ing that NADPH oxidase may be involved (Fig. 1D).
VEGF is a known, potent inducer of permeability in the
microvasculature (4). We sought to determine if the VEGF-
induced increase in microvascular permeability requires ROS,
through the use of a FITC-dextran Transwell assay to measure
endothelial cell monolayer permeability. Endothelial cells
grown to confluence on Transwell filters were stimulated with
VEGF, resulting in an increase in the passage of FITC-dextran
across the monolayers (Fig. 2A). However, this increase in per-
meability after VEGF treatment was attenuated by treatment
with the ROS scavenger, NAC. Similar results were observed
when cells were treated with DPI. Although VEGF caused an
increase in microvascular permeability, treatment with DPI
inhibited the VEGF-induced permeability increase (Fig. 2B).
Vascular permeability is regulated, in part, by the integrity of
junctions between neighboring endothelial cells. One of the
major adhesion molecules that regulates the integrity of endo-
thelial junctions is VE-cadherin. Therefore, we wanted to
determine if any visible change was occurring in the localiza-
tion of VE-cadherin after VEGF treatment (Fig. 2C). We found
that under control conditionsVE-cadherin staining is primarily
seen as a tight line bordering the endothelial cells at the cell-cell
junctions (Fig. 2C, panel a). However, upon VEGF treatment
we found that VE-cadherin staining becomes much more
jagged and that visible gaps are seen between neighboring
endothelial cells (Fig. 2C, panel c). If ROS are scavenged with
NACwe found that theVEGF-induced changes inVE-cadherin
staining are attenuated (Fig. 2C, panel d). Taken together with
Fig. 1 these data indicate that VEGF treatment leads to the
production of ROS and that these ROS are required for the
increase in microvascular permeability.
Tyrosine phosphorylation of various adherens junction
molecules in the endothelium is indicative of decreased
junctional integrity (26, 27). One of the major adhesion mol-
ecules of endothelial junctions is VE-cadherin. To determine
if VEGF treatment caused any change in the tyrosine phos-
phorylation of VE-cadherin, VE-cadherin was immunopre-
cipitated and general phosphotyrosine levels were analyzed.
As demonstrated in Fig. 3A, treatment with VEGF caused
enhanced tyrosine phosphorylation of VE-cadherin in
HMVECs. Phosphorylation of VE-cadherin at tyrosines 658
and 731 has been shown to inhibit the binding of p120-catenin
and -catenin, respectively (17). To investigate whether VEGF
treatment has any effect on the catenin binding sites of VE-
cadherin, HMVECs were treated with VEGF for increasing
amounts of time and the phosphorylation at Tyr-658 and Tyr-
731 were monitored. Treatment with VEGF caused enhanced
phosphorylation of both of these residues on VE-cadherin as
early as 5 min after treatment (Fig. 3B). To determine if ROS
were required for these VEGF-induced effects on VE-cadherin
tyrosine phosphorylation, NAC and DPI were again used (Fig.
3,C andD). In both cases we observed that VEGFwas no longer
able to cause phosphorylation of VE-cadherin after treatment
with NAC or DPI, suggesting that ROS are required for phos-
phorylation of VE-cadherin at the catenin binding sites. Similar
results were seen when -catenin was examined. Immunopre-
cipitation analysis revealed enhanced tyrosine phosphorylation
of -catenin after VEGF treatment (Fig. 4A). Examination of
Tyr-654 revealed elevated phosphorylation in response to
VEGF (Fig. 4B) that was inhibited upon NAC treatment (Fig.
4C) and treatment with DPI (Fig. 4D).
To determine if the phosphorylation of VE-cadherin at
tyrosines 658 and 731 was critical to the ability of VEGF to
FIGURE 1. VEGF treatment causes an increase in the generation of ROS.
A, confluent monolayers of HMVECs were loaded with DCF and then treated
with increasing doses of VEGF for 15 min. The generation of ROS was meas-
ured by the fluorescence intensity of DCF. B, confluent monolayers of
HMVECs were loaded with DCF and then treated with 10 ng/ml VEGF for 5, 10,
and 15 min. The generation of ROS was measured by the fluorescence inten-
sity of DCF. C and D, HMVECs were pretreated with NAC (B) or DPI (C) for 2 h.
Cells were then loaded with DCF and treated with 10 ng/ml VEGF for 10 min.
The generation of ROS was measured by the fluorescence intensity of DCF.
These are representative graphs of an n  3 performed in quadruplicate.
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induce enhanced vascular permeability, HMVECs were
infected with adenovirus containing either wild-type VE-cad-
herin (WT), VE-cadherin in which Tyr-658 was mutated to
phenylalanine (Y658F), VE-cadherin in which Tyr-731 was
mutated to phenylalanine (Y731F)
or a double mutant where both
tyrosines 658 and 731 had been
mutated to phenylalanines (Y658F/
Y731F) (Fig. 5A) (24). We first
sought to determine if mutation at
these tyrosine residues had any
effect on the ability of VEGF to
induce tyrosine phosphorylation of
VE-cadherin. Under control condi-
tions expression of any of the VE-
cadherin viruses had no effect on
basal phosphotyrosine levels (Fig.
5B). Upon stimulation with VEGF
we find that there is enhanced tyro-
sine phosphorylation of VE-cad-
herin in cells infected with the WT
virus. In cells infected with the
Y658F or Y731F viruses there is a
reduced level of tyrosine phospho-
rylation when compared with cells
infected with WT. There is even a
further reduction in VE-cadherin
tyrosine phosphorylation when the
Y658F/Y731F mutant was exam-
ined. To determine if these VE-
cadherin tyrosine residues were
critical to the ability of VEGF to
enhance microvascular permeabil-
ity, theHMVECswere infected with
theVE-cadherin viruses and perme-
ability was assessed through FITC-
dextran flux (Fig. 5C). A GFP virus
was used as a control. Under control
conditions expression of any of
the VE-cadherin viruses had no
effect on basal vascular permeabil-
ity. Upon VEGF treatment cells
infected with GFP or WT VE-cad-
herin showed an increase in vascu-
lar permeability. Infection with
either single VE-cadherin mutant
(Y658F or Y731F) had little effect on
the ability of VEGF to enhance
vascular permeability. However,
infection with the double mutant
(Y658F/Y731F) significantly de-
creased the ability of VEGF to
enhance permeability. To evaluate if
phosphorylation at Tyr-658 and
Tyr-731 was important in the regu-
lation of VE-cadherin/catenin in-
teractions, in response to VEGF
treatment, we again utilized the
VE-cadherin WT, Y658F, Y731F, and Y658F/Y731F adeno-
viral constructs. We first examined the relationship between
VE-cadherin and p120-catenin by co-immunoprecipitation
analysis. We found that in cells expressing WT VE-cadherin
FIGURE 2. VEGF induced permeability requires ROS. HMVECs were seeded in the upper well of a Transwell
chamber and allowed to grow to confluence. Cells were treated with NAC (A) or DPI (B) before 1 mg/ml
FITC-dextran (Mr 10,000) was placed in the upper well, and cells were treated with 10 ng/ml VEGF for 30 min. A
sample of medium from the lower chamber was then taken, and the amount of FITC-dextran in the lower
chamber was measured in a plate reader. These are representative graphs of an n  3 performed in quadru-
plicate. C, HMVECs were grown on coverslips and appropriate wells treated with NAC for 2 h before treatment
with VEGF for 15 min. Cells were then fixed, permeabilized, and stained with an antibody against VE-cad-
herin. Panel a, control treated cells; panel b, NAC-treated cells; panel c, VEGF-treated cells; panel d, NAC/
VEGF-treated cells.
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VEGF treatment reduced the association between VE-cad-
herin and p120-catenin (Fig. 5D). However, expression of the
Y658F mutant or the double mutant attenuated the VEGF-
induced VE-cadherin/p120-catenin dissociation. Similar
results were seen when the VE-cadherin/-catenin complex
was examined. Again, in cells expressing WT VE-cadherin
VEGF treatment caused a reduction in the amount of -cate-
nin that was complexed with VE-cadherin (Fig. 5E). How-
ever, in cells expressing the Y731F or the double mutant
VEGF was unable to induce VE-
cadherin/-catenin dissociation.
Collectively, these results suggest
that the regulation of microvascu-
lar permeability by VEGF requires,
in part, the phosphorylation of
VE-cadherin at tyrosines 658 and
731.
To further examine the integrity of
the adherens junction, a coimmuno-
precipitation analysis was performed
to look at the extent of interaction
between endogenous VE-cadherin
and -catenin. As demonstrated
in Fig. 6A, VE-cadherin and -
catenin strongly co-immunopre-
cipitate under control conditions.
However, upon treatment with
VEGF there was a reduction in the
amount of -catenin that co-immu-
noprecipitated with VE-cadherin,
suggesting that VEGF treatment
decreases the interaction between
VE-cadherin and -catenin. Treat-
ment with NAC prevented the dis-
sociation of -catenin with VE-
cadherin, suggesting that ROS are
necessary for the disruption of this
interaction. In addition to the
interaction between VE-cadherin
and -catenin we also examined
the interaction between VE-cad-
herin and p120-catenin. We found
that, under control conditions VE-
cadherin and p120-catenin co-im-
munoprecipitate (Fig. 6B). How-
ever, upon treatment with VEGF
there is a reduction in the amount
of p120 catenin that co-immuno-
precipitated with VE-cadherin.
Treatment with NAC prevented
the VEGF-induced dissociation of
VE-cadherin and p120-catenin,
suggesting that ROS are also nec-
essary for the disruption of this
interaction. Taken together, these
data suggest that VEGF-induced
ROS production regulates the
tyrosine phosphorylation of adhe-
rens junction proteins VE-cadherin, -catenin, and p120-
catenin and their association.
Previous work has demonstrated that VEGF causes the acti-
vation of Rac1 in endothelial cells (28, 29). To confirm these
observations, Rac1 GTP loading was measured by pulldown
assays with glutathione S-transferase-p21-activating kinase.
Indeed, we found that VEGF treatment caused a rapid activa-
tion of Rac1 (Fig. 7A). As we had demonstrated that ROS were
required for the increase in VEGF-induced permeability (Fig.
FIGURE 3. VEGF treatment causes ROS-dependent phosphorylation of VE-cadherin. Monolayers of
HMVECs were treated with 10 ng/ml VEGF. A, VE-cadherin was immunoprecipitated from cell lysates using a
mouse anti-VE-cadherin antibody, and the resulting immunoprecipitates were analyzed for phosphotyrosine
by immunoblotting (4G10, top) or total VE-cadherin (bottom). B, cell layers were lysed in sample buffer. Lysates
were electrophoresed, immunoblotted, and analyzed for phosphorylated forms of VE-cadherin using antibod-
ies that specifically recognize VE-cadherin phosphorylated at tyrosines 658 and 731. Total VE-cadherin was
used as a loading control. C and D, HMVECs were pretreated with NAC (C) or DPI (D) before treatment with 10
ng/ml VEGF, and the phosphorylation of VE-cadherin was monitored by Western blotting.
FIGURE 4. VEGF treatment causes ROS-dependent phosphorylation of -catenin. Monolayers of HMVECs
were treated with 10 ng/ml VEGF. A, -catenin was immunoprecipitated from cell lysates using a mouse
anti--catenin antibody, and the resulting immunoprecipitates were analyzed for phosphotyrosine by immu-
noblotting (4G10, top) or total -catenin (bottom). B, cell layers were lysed in sample buffer. Lysates were
electrophoresed, immunoblotted and analyzed for a phosphorylated form of -catenin using an antibody that
specifically recognizes -catenin phosphorylated at tyrosine 654. Total -catenin was used as a loading con-
trol. C and D, HMVECs were pretreated with NAC (C) or DPI (D) before treatment with 10 ng/ml VEGF, and the
phosphorylation of -catenin was monitored by Western blotting.
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2), we wondered whether ROS might also be required for the
VEGF-induced activation of Rac. To determine this we treated
cells with NAC before VEGF treatment and then performed a
PAK-binding domain pulldown assay to analyze the levels of
active Rac. We found that scavenging ROS with NAC had no
effect on the ability of VEGF to activate Rac (Fig. 7B). Once we
had determined that ROS were not required for Rac activation
we wondered if the inverse might be true.Was Rac required for
ROS production in response to VEGF treatment? To answer
this question we used RNA interference to knock down Rac1
expression in HMVECs (Fig. 8A), and the ability of VEGF to
induce ROS formation was measured. We observed that under
control non-targeting siRNA conditions VEGF treatment
resulted in an increase in ROS pro-
duction. However, in cells where
Rac expression had been knocked
down the ability of VEGF to
induce ROS was greatly attenu-
ated (Fig. 8B).
Once we had demonstrated that
Rac was required for VEGF-induced
ROS formation we asked whether
Rac might also be required for
VEGF-induced VE-cadherin phos-
phorylation, because we had already
shown this to be ROS-dependent.
RNA interference was again used to
knock down Rac1 expression, and
the ability of VEGF to induce phos-
phorylation of VE-cadherin at the
catenin binding sites (Tyr-658 and
Tyr-731) was monitored. We ob-
served that cells transfected with
Rac1 siRNA show a severe attenua-
tion in the VEGF-induced VE-cad-
herin phosphorylation, as com-
paredwith the cells transfectedwith
a non-targeting siRNA (Fig. 9).
Finally, we sought to determine
whether Racwas also required for the
VEGF-mediated increase in micro-
vascular permeability. As shown in
Fig. 10, cells transfected with a non-
targeting siRNA are able to enhance
vascular permeability upon VEGF
treatment. However, knockdown of
Rac1 abrogates the VEGF-induced
permeability effect. Taken together
our data demonstrate that Rac1
activation is necessary for VEGF-
mediated vascular permeability and
that the activation of Rac is required
upstream of ROS generation in this
pathway.
DISCUSSION
VEGF has a well known and well
studied role in angiogenesis. How-
ever, the molecular mechanisms that regulate VEGF-in-
duced permeability in the microvasculature, the first
described function of VEGF, remain incompletely under-
stood (4, 5). Recent studies have sought to determine the
pathways through which VEGF regulates vascular perme-
ability; however, these studies have focused primarily on
HUVECs, endothelial cells from large vessels and not on cells
of the microvasculature. Because the microvasculature rep-
resents the vessels where the largest changes in permeability
occur and because VEGF is known to greatly alter microvas-
cular permeability, the focus of this study was to determine
the mechanism through which VEGF regulates microvascu-
lar permeability. We found that VEGF regulates microvas-
FIGURE 5. VE-cadherin mutation dampens VEGF-induced permeability. HMVECs were infected with ade-
novirus containing, WT VE-cadherin, or mutant VE-cadherins Y658F, Y731F, or Y658F/Y731F. A, cells were lysed
and lysates were analyzed for the expression of both GFP-VE-cadherin and endogenous VE-cadherin by West-
ern blot. B, cells were treated with 10 ng/ml VEGF for 15 min and lysed. GFP was immunoprecipitated from cell
lysates using a mouse anti-GFP antibody, and the resulting immunoprecipitates were analyzed for phospho-
tyrosine by immunoblotting (4G10, top) or total VE-cadherin (bottom). C, cells were seeded in the upper well of
a Transwell chamber and allowed to grow to confluence. 1 mg/ml FITC-dextran (Mr 10,000) was placed in the
upper well, and cells were treated with 10 ng/ml VEGF for 30 min. A sample of medium from the lower chamber
was then taken and the amount of FITC- dextran in the lower chamber was measured in a plate reader. D, cells
were treated with 10 ng/ml VEGF for 15 min. GFP was immunoprecipitated from cell lysates, and immunopre-
cipitates were blotted for the presence of p120-catenin (top) and VE-cadherin (bottom). E, cells were treated
with 10 ng/ml VEGF for 15 min. GFP was immunoprecipitated from cell lysates, and immunoprecipitates were
blotted for the presence of -catenin (top) and VE-cadherin (bottom). *, p  0.05 Student’s t test.
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cular permeability through the activation of Rac1 and the
production of ROS. These molecules, in turn, regulate the
tyrosine phosphorylation of adherens junction proteins VE-
cadherin and -catenin, ultimately regulating junctional
integrity.
Until recently, ROS production in non-phagocytic cells
has been viewed primarily as a harmful byproduct of various
metabolic activities that cause DNA damage and lead to the
oxidation of membrane proteins and lipids. In phagocytic
cells there is a Rac-activated NADPH oxidase that generates
ROS (30). However, the identification of a Rac-regulated
NADPH oxidase in non-phagocytic cells raised the possibility
that ROS served other functions (31). Numerous studies have
shown that ROS increase permeability both in vitro and in vivo
(32, 33). Our results show that VEGF leads to ROS production
in themicrovasculature and that these ROS are required for the
increase in permeability observed in response to VEGF treat-
ment. Consistent with our results, earlier work has demon-
strated that VEGFwill increase superoxide production in endo-
thelial cells of larger vessels and that this is required for the
angiogenic phenotype (34). Furthermore, growth factors,
including platelet-derived growth factor and EGF stimulate the
generation of ROS (21, 35). In ischemia reperfusion injury, the
generation of ROS derives fromboth the endothelium aswell as
from activated leukocytes, and the
associated increase in permeability
has been shown to be inhibited by
antioxidants and free radical scav-
engers (32). Likewise, we demon-
strate that the VEGF-induced vas-
cular permeability is also attenuated
by NAC, a free radical scavenger,
and DPI, a flavoprotein inhibitor.
These studies contribute to the
increasing recognition that ROS
have a role in signal transduction
pathways that regulate diverse cel-
lular responses, including migra-
tion, growth, and differentiation
(36).
NADPHoxidase is amajor source
of ROS production in endothelial
cells (25), and Rac1 is a critical com-
ponent of endothelial NADPH oxi-
dase (25, 37). Appropriate levels of
active Rac are required for the for-
mation and maintenance of adher-
FIGURE 6. VEGF treatment causes the ROS-dependent dissociation of VE-cadherin and -catenin and
VE-cadherin and p120-catenin. HMVECs were pretreated with NAC for 2 h before treatment with 10 ng/ml
VEGF for 15 min. VE-cadherin was immunoprecipitated from cell lysates, and immunoprecipitates were blotted
for the presence of -catenin (A) and p120-catenin (B).
FIGURE 7. VEGF treatment leads to the activation of Rac. A, HMVECs were treated with 10 ng/ml VEGF for increasing time, and the activation of Rac was
measured through a GST-PAK-binding domain pulldown assay as described under “Experimental Procedures.” B, HMVECs were pretreated with NAC before
treatment with VEGF. The activation of Rac was measured through a GST-PAK-binding domain pulldown assay.
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ens junctions and either too high or too low activities promote
disassembly. Both constitutively active and dominant negative
Rac increase endothelial permeability, consistent with the level
of Rac needing to be finely tuned for optimal junctional integ-
rity (38). In addition, several groups have demonstrated that
activation of Rac1 in response to sphigosine 1-phosphate
enhances barrier function of endothelial monolayers (39,
40). However, we and others have shown that activation of
Rac1 downstream of VEGF, and other growth factors, pro-
motes junction disassembly and increase permeability (18,
41–43). In addition, VEGF has been observed to regulate
endothelial cell permeability through PAK, a direct down-
stream effector of Rac (44). It seems that it is more complex
than simply high Rac activation leading to increased perme-
ability. That active Rac can both increase and decrease per-
meability depending on the stimulus leads us to suggest that
the route of activation may be critical and that different scaf-
folding proteins may direct Rac signaling pathways in differ-
ent directions.
Tyrosine phosphorylation of adherens junction proteins
has long been associated with the disassembly of cell-cell
adhesions, although the precise mechanism has not been
resolved (26, 27, 45). Several proteins, including cadherins
and catenins, become prominently tyrosine-phosphorylated
when PTPs are inhibited or when tyrosine kinases are acti-
vated. A number of PTPs, including VE-PTP, PTP, and
SHP-2, can influence VE-cadherin function by altering its
tyrosine phosphorylation state (46–49). VEGF treatment
can disrupt the association between VE-cadherin and VE-
PTP resulting in enhanced tyrosine phosphorylation of VE-
cadherin and decreased barrier function (50). ROS oxidize a
critical cysteine residue in the catalytic site of tyrosine phos-
phatases, thereby deactivating these enzymes, resulting in
increased tyrosine phosphorylation (51). VEGF treatment
also induces Src activation, which leads to the tyrosine phos-
phorylation of several junctional proteins (52, 53). Additional
work has demonstrated that Src inhibition or deficiency results
in defective VEGF-induced vascular permeability due to the
stabilization of VE-cadherin in endothelial cell junctions (52,
54). Within the endothelium, elevated tyrosine phosphoryla-
tion is associated with a decrease in barrier function (55–58).
Our data demonstrate that VEGF treatment leads to the tyro-
sine phosphorylation of VE-cadherin on at least two sites that
lie within the -catenin and p120 catenin binding regions.
Additionally, we show that VEGF treatment results in -cate-
nin phosphorylation itself. The tyrosine phosphorylation of
VE-cadherin at Tyr-731 has been reported to cause a loss in the
ability of VE-cadherin to bind -catenin (17). Additionally,
tyrosine phosphorylation of-catenin has also been reported to
decrease its affinity for the cadherin and increase its turnover at
junctions (59, 60). Although the enhanced phosphorylation of
VE-cadherin at Tyr-731 changes the binding affinity for-cate-
nin and likely decreases cytoskeletal attachment, the phospho-
rylation at Tyr-658 decreases the affinity of VE-cadherin for
p120 catenin (17). It has been demonstrated that the binding of
p120 to VE-cadherin prevents VE-cadherin internalization
thereby acting to stabilize the junction (61). The tyrosine phos-
phorylation of VE-cadherin at these catenin binding sites sug-
gests that VEGF may be regulating microvascular permeability
through mechanisms controlling both cytoskeletal attachment
and junctional stability.
Our data provide new insight into the molecular mecha-
nisms by which VEGF regulates permeability of the microvas-
culature. In this work we have identified a pathway by which
FIGURE 8. Rac is required for VEGF-induced ROS generation. A, HMVECs
were transfected with Rac siRNA or non-targeting siRNA for 72 h. Cells were
then lysed in sample buffer, electrophoresed, and immunoblotted with an
antibody against Rac1 or actin. B, HMVECs were transfected with Rac siRNA or
a non-targeting siRNA for 72 h. Cells were then treated with10 ng/ml VEGF
and ROS generation was monitored by DCF fluorescence.
FIGURE 9. Rac is required for VEGF-induced VE-cadherin phosphoryla-
tion. HMVECs were transfected with Rac siRNA or non-targeting for 72 h. Cells
were then treated with 10 ng/ml VEGF. Cells were lysed in sample buffer, and
lysates were electrophoresed and immunoblotted with antibodies against
VE-cadherin phosphorylated at Tyr-658 and Tyr-731. Total VE-cadherin was
used as a loading control.
FIGURE 10. Rac is required for VEGF-induced permeability. HMVECs were
transfected with Rac siRNA or non-targeting for 72 h. Cells were seeded in the
upper well of a Transwell chamber and allowed to grow to confluence. 1
mg/ml FITC-dextran (Mr 10,000) was placed in the upper well, and cells were
treated with 10 ng/ml VEGF for 30 min. A sample of medium from the lower
chamber was then taken, and the amount of FITC-dextran in the lower cham-
ber was measured in a plate reader.
VEGF-induced Permeability Requires Rac and ROS
SEPTEMBER 18, 2009 • VOLUME 284 • NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 25609
VEGF increases endothelial permeability, demonstrating that
VEGF leads to a Rac-mediated generation of ROS, which, in
turn, elevates the tyrosine phosphorylation of several junctional
proteins, including VE-cadherin and -catenin. Rac activation
andROS generation have been implicated inmany pathological
situations where vascular permeability is altered. It will be
interesting to determinewhether these can also be attributed to
the enhanced tyrosine phosphorylation of VE-cadherin and
-catenin.
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